OR WAIT null SECS
Sterling Pharma Solutions has announced a £10 million (US$13.5 million) investment into process development and manufacturing capacity at its site in Dudley, UK.
Global contract development and manufacturing organization (CDMO), Sterling Pharma Solutions, has announced a £10 million (US$13.5 million) investment into process development and manufacturing capacity at its site in Dudley, United Kingdom.
This latest investment, which forms part of a multi-year investment strategy being undertaken by Sterling at its Dudley site, will involve the building and commissioning of new process development laboratories, as well as the installation of additional commercial-scale manufacturing equipment to meet growing demand for small-molecule API manufacturing.
Equipment to be installed include a 4.5 cubic meter hydrogenator, which is capable of press reactions up to 10 bar, in addition to supplemental conical and filter dryers in the existing manufacturing plant. Furthermore, new kilo-scale and technology laboratories will be built at the Material Science Centre, located on the same site. Completion of the project is expected by mid-2022.
“The next phase of our strategic plan is to increase and enhance our capacity to develop and scale up processes for commercial readiness, and is testament to the continued, strong interest that we are seeing in small molecule development,” said Kevin Cook, CEO at Sterling, in the press release. “Having the capabilities and expertise across a range of advanced technologies is crucial to ensure that Sterling can continue to be an industry-leading partner for API development and manufacturing, and meet the future demands of our customers.”
Source: Sterling Pharma Solutions